<span lang="EN-GB"></span> <font face="Times New Roman" size="3"> </font> <span lang="EN-GB"></span>

 

 

<span lang="EN-GB"></span>

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.

Company

Company

Remimazolam

Remimazolam

Media and Investors

Media and Investors

PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S.

PAION's Remimazolam

news

12/21/2018

Ad hoc release: PAION announces submission of New Drug Application for...

PAION announces submission of New Drug Application for...

Read more
11/16/2018

Ad hoc release: PAION announces that NMPA accepts submission of New Drug...

PAION announces that NMPA accepts submission of New Drug...

Read more
11/07/2018

Quarterly Statement for the first nine months of 2018

Quarterly Statement for the first nine months of 2018

Read more
03/09/2017

Press Release: PAION AG: Change in Management Board

PAION AG: Change in Management Board

Read more
02/28/2017

Press Release: PAION AG announces successful completion of capital increase with...

PAION AG announces successful completion of capital increase with...

Read more
02/07/2017

Press Release: PAION AG: Capital increase; preliminary, unaudited key group...

PAION AG: Capital increase; preliminary, unaudited key Group...

Read more
12/21/2016

Press Release: PAION announces clinical development progress with remimazolam by...

PAION announces clinical development progress with remimazolam by...

Read more
10/19/2016

Press Release: Positive Remimazolam phase III colonoscopy results presented at...

Positive Remimazolam phase III colonoscopy results presented at...

Read more
09/22/2016

Press Release: Remimazolam Phase III colonoscopy data to be presented at the...

Remimazolam Phase III colonoscopy data to be presented at the...

Read more
09/06/2016

Press Release: PAION announces clinical development progress with remimazolam by...

PAION announces clinical development progress with remimazolam by...

Read more
06/29/2016

Press Release: PAION completes private placement in the amount of EUR 9.6...

PAION completes private placement in the amount of EUR 9.6...

Read more
06/19/2016

Press Release: PAION reports positive remimazolam headline data in pivotal U.S....

PAION reports positive remimazolam headline data in pivotal U.S....

Read more
04/11/2016

Press Release: PAION successfully completes patient recruitment in Phase III...

PAION successfully completes patient recruitment in Phase III...

Read more
To the newsroom

PAION Chart

 

Visit us on LinkedIn!
LinkedIn